RNS Number : 8108Q
Valereum PLC
29 January 2026

Date: 29 January 2026

FOR IMMEDIATE RELEASE (Aquis Stock Exchange: VLRM)

Valereum Plc
("Valereum", "VLRM" or the "Company")

Memorandum of Understanding with Injective Foundation and DigiShares

Exercise of Warrants and Total Voting Rights

Valereum Plc (AQSE: VLRM), a company aiming to be the global market leader in the rapidly developing tokenised digital markets sector, is pleased to announce that it has entered into a non-binding Memorandum of Understanding ("MoU"), with Injective Foundation ("Injective"), a leading Layer-1 blockchain for decentralised finance, and DigiShares, Inc. ("DigiShares"), a provider of tokenisation and issuance technology for real-world assets ("RWAs").

The MoU establishes a strategic framework for collaboration across the Injective blockchain, the Valereum ecosystem (including VLRM Markets, S.A. de C.V.), and the DigiShares platform. Together, we aim to deliver compliant RWA tokenisation, secondary trading, and ecosystem development by leveraging decentralised finance infrastructure.

Key benefits the MoU aims to deliver:

- Injective to be a strong blockchain L1 partner with marketing to its ecosystem
- New users from qualified retail, HNW, family office, funds and other institutions anticipated to onboard to VLRM Markets' platform (via DigiShares)
- Increase in secondary trading & liquidity access
- Moving closer to realising opportunities such as building an RWA DEX on Injective

Injective Integration and RWA Issuance

The parties will focus on an imminent integration of Injective's EVM-compatible Layer-1 with the DigiShares primary issuance platform, enabling RWAs issued through DigiShares to be minted directly onto the Injective blockchain, subject to technical and regulatory review.

VLRM Markets, Valereum's licensed and regulated Digital Asset Service Provider in El Salvador, will support a multi-chain issuance strategy, with issuances being minted on Injective's EVM infrastructure.

Injective will support ecosystem development by promoting VLRM Markets within its network, providing introductions to participants in the RWA sector.

The collaboration opens up broader optionality beyond the Valereum platform. Through DigiShares' client base of approximately 200 issuers, the integration is expected to enable additional RWA issuances to be minted on Injective's infrastructure, independently of VLRM Markets. These issuances would benefit from exposure within the Injective ecosystem, with the potential for decentralised secondary trading and liquidity access (as supporting infrastructure becomes available, subject to regulatory and technical considerations).

Secondary Trading, Liquidity and Market Infrastructure

The parties will explore secondary trading enablement for qualifying RWA tokens through Injective's on-chain order book and decentralised exchange infrastructure. This would support transparent price discovery and liquidity,

complementing VLRM Markets' regulated venue which can also be extended to DigiShares' clients minting on Injective EVM. The parties will also evaluate market-making and liquidity support initiatives, alongside broader ecosystem collaboration to attract institutional and professional buy-side participation.

Standards, Interoperability and Ecosystem Development

Valereum and Injective plan to join DigiShares and participate in the ERC-7943 standard, which is expected to be the new leading standard for RWAs and digital securities.

All areas of collaboration will proceed according to staged technical, regulatory and commercial assessment prior to implementation.

Exercise of Warrants

Valereum has received a notice of exercise from Fortified Securities of 1,000,000 warrants over new ordinary shares of £0.001 each in the Company (the "New Ordinary Shares") at an exercise price of 4p per share, resulting in the Company receiving proceeds of £40,000.

Application will be made for the 1,000,000 New Ordinary Shares which will rank pari passu with the existing Ordinary Shares in issue, to be admitted to trading on the Aquis Growth Market ("Admission"). Dealings are expected to commence on or around 3 February 2026.

Conditional on Admission, the Company's issued ordinary share capital will comprise 488,932,742 ordinary shares of £0.001 each, all carrying voting rights. This figure may be used by shareholders as the denominator for determining whether they are required to notify the Company of their interest in, or a change to their interest in, the Company's securities pursuant to the Company's Articles.

Mark Mariampillai, Commercial Director of VLRM Markets, comments:

"*I'm extremely excited about our collaboration with Injective Foundation and DigiShares, which brings together institutional-grade regulated market infrastructure, best-in-class issuance technology and a leading Layer-1 blockchain to advance real-world asset tokenisation. The initial focus will be on primary issuance, starting with Wageen and an expected TVL on-chain of up to $20 million, followed by a broader pipeline across multiple asset classes. As the partnership develops, we see a clear path to integrating on-chain secondary trading and DeFi-enabled use cases, positioning Valereum at the centre of the next phase of growth in the RWA sector."*

Cooper Emmons Business Development of Injective Foundation added:

"We are pleased to work with Valereum and DigiShares to support compliant real-world asset issuance infrastructure. This collaboration reflects Injective's commitment to expanding institutional-grade DeFi use cases through interoperable and scalable blockchain technology."

Claus Skaaning, CEO of DigiShares, commented:

"This collaboration brings together regulated market infrastructure, institutional issuance technology, and decentralised trading capabilities. Working alongside Valereum and Injective allows us to expand interoperable RWA issuance options for issuers, while maintaining a strong focus on compliance and scalability."

For further information, please contact:

Valereum Plc Karl Moss	Tel: +44 7938 767319 Investor Hub
Fortified Securities Guy Wheatley	Tel: +44 203 4117773

Aquis Corporate Adviser Guild Financial Advisory Limited Ross Andrews	E: ross.andrews@guildfin.co.uk

To read more, please visit the Company's website at www.vlrm.com
or
To engage with Valereum directly by asking questions, watching video summaries and seeing what other shareholders have to say, navigate to our **Investor Hub here: Sign Up**

About DigiShares

DigiShares is a leading provider of white-label platforms for the compliant tokenisation of real-world assets (RWA), including real estate, private equity, and infrastructure. The platform enables businesses to issue, manage, and trade digital securities using blockchain technology, streamlining investor onboarding (KYC/AML), smart contract-based ownership, and peer-to-peer secondary trading. Known for its institutional-grade compliance features and flexibility. Learn more: https://digishares.io. Valereum Plc holds a minority stake in DigiShares.

About Injective Foundation

Injective is a high-performance, interoperable Layer-1 blockchain built specifically for financial applications and decentralized markets. It provides a regulated and scalable infrastructure where developers and institutions can deploy real-world asset tokenisation, on-chain trading, derivatives, and other advanced financial services with fast finality, low costs and cross-chain interoperability. Backed by an active ecosystem and designed to bridge traditional finance and decentralised finance, Injective offers enterprise-grade modules and marketplace primitives that enable compliant, transparent and efficient capital markets on blockchain technology.

IMPORTANT NOTICES

The Company holds cryptocurrencies or cryptoassets in its treasury. Whilst the Board of Directors of the Company considers holding cryptocurrencies to be in the best interests of the Company, the Board remains aware that the financial regulator in the UK (the Financial Conduct Authority or FCA) considers investment in cryptocurrencies to be high risk. At the outset, it is important to note that an investment in the Company is not an investment in cryptocurrencies, either directly or by proxy and shareholders will have no direct access to the Company's holdings. However, the Board of Directors consider cryptocurrencies to be an appropriate store of value and potential growth and therefore appropriate for the Company. Accordingly, the Company is and intends to continue to be materially exposed to cryptocurrencies.

The Company is neither authorised nor regulated by the FCA, and the purchase of certain cryptocurrencies are generally unregulated in the UK. As with most other investments, the value of cryptocurrencies can go down as well as up, and therefore the value of the Company's cryptocurrencies holdings can fluctuate. The Company may not be able to realise its cryptocurrencies holdings for the same as it paid to acquire them or even for the value the Company currently ascribes to its cryptocurrencies positions due to market movements. Neither the Company nor investors in the Company's shares are protected by the UK's Financial Ombudsman Service or the Financial Services Compensation Scheme.

Cryptocurrencies may present special risks to the Company's financial position. These risks include (but are not limited to): (i) the value of cryptocurrencies can be highly volatile, with value dropping as quickly as it can rise. Investors in cryptocurrencies must be prepared to lose all money invested in cryptocurrencies; (ii) the cryptocurrencies market is largely unregulated. There is a risk of losing money due to risks such as cyber-attacks, financial crime and counterparty failure; (iii) the Company may not be able to sell its cryptocurrencies at will. The ability to sell cryptocurrencies depends on various factors, including the supply and demand in the market at the relevant time. Operational failings such as technology outages, cyber-attacks and comingling of funds could cause unwanted delay; and (iv) cryptoassets are characterised in some quarters by high degrees of fraud, money laundering and financial crime. Prospective investors in the Company are encouraged to do their own research before investing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUWOKRNBUAUAR